Full-Time
Product Manager
Rare Disease
Updated on 9/3/2026
Ipsen Global
5,001-10,000 employees
Global biopharma focused on specialty care
Compensation Overview
CA$95k - CA$138k/yr
Mississauga, ON, Canada
In Person
Bachelor's, Master's, MBA
 Product (1) |
|---|
Get referred to Ipsen Global
See people who can refer or advise you
- A bachelor's degree is required.
- Five years of experience in the biotechnology or pharmaceutical industry are required.
- Two years of progressive marketing or related experience are required.
- Two years of experience in sales, preferably specialty care, are required.
- Demonstrated ability to build relationships, foster trust, gain respect, lead, motivate, collaborate, negotiate, and influence the decision-making of internal and external stakeholders is required.
- Demonstrated understanding of how customers use information across all channels and experience leveraging multiple channels to achieve brand objectives are required.
- Knowledge of pharmaceutical legal, regulatory, and medical processes is required.
- Proven leadership, strategic, and analytical abilities are required.
- Proven skills in strategic planning and product launches are required.
- Demonstrated project management skills and the ability to manage multiple priorities in a fast-paced environment are required.
- Demonstrated experience working with and managing agency partners is required.
- Strong team-building skills and a team-oriented approach are required.
- Strong written and oral communication skills are required.
- Strong presentation and facilitation skills are required.
- The ability to develop consistent, well-supported, competitive strategies is required.
- The ability to act with a high sense of urgency is required.
- Adaptability and the ability to advocate for change are required.
- Support the development and delivery of annual strategic and tactical plans for the brand.
- Identify market opportunities, industry trends, and customer targets through competitive analysis, positioning, and marketing strategy assessments.
- Integrate information and data across functions and geographies, as well as external knowledge, to generate insights that drive the business forward.
- Leverage and align the expertise of key cross-functional stakeholders, including Medical, Regulatory Affairs, Market Access, and Stakeholder Relations, to deliver insights and solutions geared to patient and physician needs.
- Design and execute marketing research to generate insights that drive the strategic plan.
- Develop focused strategic and tactical plans for the brands, including monitoring goals, with specific understanding of the pharmacy and specialty care markets.
- Communicate strategic and tactical plans to United States and Canadian senior management and the Specialty Sales Force.
- Support the development of promotional materials, programs, and training initiatives, and work with Legal, Medical, and Regulatory to have them reviewed and approved.
- Track critical elements of brand performance, including financial and non-financial measures, and recommend course corrections early and as needed.
- Determine effective marketing communication channels to raise awareness and understanding of Ipsen's therapy for selected patient types and develop and deploy tactics to achieve marketing plan goals.
- Partner with Finance to ensure optimal and timely use of allocated financial resources and fulfil the cadence of brand tasks related to financial management.
- Partner with Supply Chain to manage the inventory and production forecast process.
- Support forecasting and pricing teams on an ad hoc basis.
- Establish a regular cadence of cross-functional brand team meetings.
- Interact with and manage agency partners regularly to ensure smooth and timely implementation of critical tactics under the tactical plan.
- Work closely with the Associate Director of Stakeholder Relations on the Key External Expert plan of action.
- Invest time in the field with representatives to hear first-hand about physicians and payors and use those insights to inform brand plans.
- Create a culture of breakthrough thinking and pragmatic experimentation across the organization.
- Participate in above-country working groups to proactively share Canadian innovation.
- Work with other functions to develop and implement a best-in-class Canadian commercial development plan for the product.
- Work with Medical Affairs to design high-value educational programming in response to identified interests and needs of physicians and patients.
- A master's degree, preferably in business (MBA) or health sciences, is preferred.
- Specialty product marketing experience is an asset.
- Experience in rare disease or specialty care is preferred.
- Ability to speak French is an asset.
Ipsen is a global biopharmaceutical company that concentrates on specialty care, developing and marketing medicines for oncology, neuroscience, and rare diseases. Its products work by treating specific high-need conditions, ranging from historical diarrhea treatment Smecta to modern targeted therapies in cancer and neurological disorders. The company differentiates itself through a focused portfolio in niche therapeutic areas, growth via strategic acquisitions, and a long-standing family heritage that shaped its international expansion and IPO-driven capital for expansion. Its goal is to address unmet medical needs worldwide by providing effective therapies for patients with serious or rare conditions.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boulogne-Billancourt, France
Founded
2005
Get referred to Ipsen Global
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales rose 23.5% and core operating margin reached 38.6%.
- Ipsen raised 2026 guidance above 20% sales growth after strong July 2026 momentum.
- June 2026 Dysport migraine Phase III wins and Iqirvo data expand near-term growth drivers.
What critics are saying
- July 24, 2026: Bylvay failed Phase III BOLD in biliary atresia, crushing expansion hopes.
- Generic lanreotide threatens Somatuline from 2026, risking Ipsen’s cash engine within 12 months.
- Kartos navtemadlin and Memo potravitug hinge on 2027 data; failure weakens pipeline replacement.
What makes Ipsen Global unique
- Ipsen owns Somatuline, Dysport, and Bylvay across oncology, rare disease, neuroscience.
- July 2026: Ipsen strengthened late-stage pipeline with Memo Therapeutics and Kartos acquisitions.
- Ipsen’s global footprint spans 40 countries, supporting launches and reimbursement in 100 countries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Wellness Program
Flexible Work Hours
Hybrid Work Options
Remote Work Options
Paid Vacation
Company News
Ipsen and Galderma's Dysport faces increasing competition in the global neurotoxin market from established products like Botox and newer entrants such as long-acting Daxxify from Revance Therapeutics. A new ResearchAndMarkets.com report analyses Dysport's sales trajectory through 2034 across seven major markets, including the US, Germany, France, Italy, Spain, the UK, and Japan. The botulinum toxin procedures market is projected to reach approximately $11.3 billion by 2028, with an estimated 8% compound annual growth rate. Galderma's neuromodulator sales reached $1.47 billion in 2025, up 14.3% year-over-year from $1.29 billion in 2024. Dysport maintains its market position through competitive pricing, clinical efficacy, and applications across both aesthetic and therapeutic indications, though Botox remains the global market leader.
Marengo Therapeutics has nominated its first drug candidate under its strategic collaboration with Ipsen, advancing the programme into IND-enabling development. The candidate is the second from Marengo's TriSTAR platform to reach this stage. The company also appointed Saso Cemerski as senior vice president, head of immunology, to expand its T-cell engager pipeline. TriSTAR is a precision T-cell engager platform combining selective T-cell activation with tumour-directed engagement in a single molecule. The milestone demonstrates progress across multiple programmes under the collaboration, which was established in June 2024. Marengo led research and preclinical development for this programme and is eligible for milestone payments. Ipsen will assume responsibility for all subsequent development activities.
Ipsen reported strong first-half 2026 results, with sales growing 23.5% at constant exchange rates to €2.19bn and core operating income rising 28.8% to €845m. The French biopharmaceutical company upgraded its full-year guidance, now expecting sales growth above 20% at constant rates, up from previous guidance of 13%. The company strengthened its pipeline with positive Phase III results for Dysport in migraine prevention and Iqirvo in primary biliary cholangitis. Ipsen completed the acquisition of Memo Therapeutics for €200m upfront, with potential milestone payments exceeding €700m. It also agreed to acquire Kartos Therapeutics for $450m upfront and up to $1.3bn in milestones, with topline data from Kartos's lead asset expected in 2027. Core operating margin reached 38.6%, with full-year expectations raised to above 37%.
Ipsen nominates Catherine Bradley to its Board of Directors as independent Director. By GlobeNewswire July 30, 2026 Ipsen appoints Catherine Bradley as independent Director to its Board of Directors PARIS, FRANCE, 29 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Catherine Bradley, CBE, as an independent Director to its Board of Directors, effective immediately. Ms. Bradley succeeds Ms. Witts who stepped down from the Board following the Annual General Meeting held on 13 May 2026. With more than 3 decades of experience in investment banking and international financial markets, followed by more than ten years of experience as a non-executive director, Ms. Bradley is a recognized expert in the financial sector and corporate governance. She has held senior leadership positions at leading global financial institutions including Merrill Lynch, Crédit Suisse and BNP Paribas. She also has specific experience in audit committee governance, having chaired the audit committees of the FCA (Financial Conduct Authority) and Aberdeen plc in the United Kingdom, Groupe Peugeot SA in France and Worldpay LLC in the United States. She currently serves as a non-executive director on several boards, notably as Chair of Interactive Investor Limited, as well as at Johnson Electric Holdings Limited in Asia, and easyJet plc, where she chairs the Finance Committee. Ms. Bradley is a graduate of HEC Paris, where she specialized in finance and international economics. Ms. Bradley is a Commander of the Order of the British Empire (CBE). The Board of Directors has also appointed Ms. Bradley as Chair of the Audit Committee and a member of the Compensation Committee. Her appointment will be submitted for ratification at the next Annual Shareholders' Meeting and, if ratified, will continue for the remainder of Ms. Witts' term of office, until the Annual Shareholders' Meeting to be held in 2029. Following this appointment, Ipsen's Board of Directors continues to comprise 14 directors, with equal representation of seven women1 and seven men. The Board includes four independent directors and two employee representatives. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. | Ipsen Contacts Advertisement | / | / | | Investors | / | / | | Henry Wheeler | [email protected] | +33 7 66 47 11 49 | | Khalid Deojee | [email protected] | +33 6 66 01 95 26 | | Media | / | / | | Sally Bain | [email protected] | +1 857 320 0517 | | Anne Liontas | [email protected] | +33 7 67 34 72 96 | Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipsen.com. 1 Representing 42%, with directors representing employees not taken into account in this calculation, pursuant to article L. 225-18-1 of the French Code of Commerce
Ipsen's rare disease drug Bylvay (odevixibat) failed to meet its primary endpoint in a Phase III trial for biliary atresia, causing the company's stock to fall. The BOLD trial enrolled 254 patients across 19 countries who had undergone Kasai hepatoportoenterostomy surgery within their first 90 days of life. The study did not demonstrate improvement in native liver survival versus placebo. Biliary atresia, affecting one in 5,000-20,000 newborns, is the leading cause of paediatric liver transplant, with no approved medical treatments beyond surgery. Bylvay is approved in the US and EU for treating cholestatic pruritus in Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome. The drug generated €180 million for Ipsen in 2025, up 32.5% from the previous year.